Pharmacology Watch
RSSArticles
-
CDC Advisory Committee Recommends Against Live Attenuated Influenza Vaccine
The decision came after a committee reviewed data showing vaccine effectiveness for the live attenuated influenza vaccine of only 3%.
-
FDA Actions
In this section: FDA approves a subdermal buprenorphine implant for maintenance treatment of opioid dependence; warns health professionals against using ketoconazole for the treatment of skin and nail fungal infection; investigates a possible link between canagliflozin and an increase in leg and foot amputations; advises against using fluoroquinolones for common infections; and green lights daclizumab for the treatment of relapsing multiple sclerosis.
-
Research: Using Generic Drugs Could Lead to Billions in Savings
If therapeutic substitution of a generic within the same class had been used instead of the branded equivalent, $73 billion could have been saved, including nearly $25 billion in out-of-pocket expenditures for patients.
-
FDA Actions
Agency approves first biosimilar for infliximab, issues warning about Abilify, announces brand name change for Brintellix, greenlights pimavanserin, and brings to market first generic version of rosuvastatin.
-
Clinical Brief Notes
Researchers make progress on Ebola vaccine and diabetes treatments.
-
Study Scrutinizes Smoking Cessation Drug Risk
The neuropsychiatric risks of smoking cessation drugs may have been overstated, according to an FDA-requested study.
-
Review of Antibiotic Prescriptions Reignites Call for More Stewardship Programs
About one-third of outpatient antibiotic prescriptions may be inappropriate, according to a new study.
-
FDA Actions
In this section: boxed warning to all immediate-release opioids; eased restrictions on mifepristone used with misoprostol used for medical abortions; reslizumab for the maintenance treatment of severe asthma; and ixekizumab for the treatment of adults with moderate-to-severe plaque psoriasis.
-
New Guidelines for Dual Antiplatelet Therapy
The guideline recommends a minimal therapy duration of 6-12 months, while therapy beyond 12 months should be reserved for patients at the highest risk of a vascular event.
-
More Evidence Supports Timing Hypothesis for Hormone Therapy
More evidence that supports the timing hypothesis (or the critical window-of-opportunity hypothesis) for hormone therapy to slow atherosclerosis progression.